Vancouver, BC / ACCESSWIRE / June 27, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC Pink: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that CEO Clips will be running a series of commercials on Canada's Business News Network ("BNN") advertising the Company's upcoming BTV Business Television segment are to be shown on July 19th and July 20th.
CEO Clips, a news/media organization profiling some of the most innovative publicly traded companies in North America, will feature a 15 to 30 second commercial advertising the Company's upcoming BTV Business Television segment to be aired on July 19th and July 20th. The segment features Mike Withrow, President of Abattis discussing the industry, company, and upcoming catalysts from its Phytalab location in Seattle. The commercials are currently airing from June 25th through June 29th, July 14th through July 20th, and August 18th through August 24th on BNN.
The CEO Clips commercial can also be viewed online at: http://www.ceoclips.com/SingleCommercial.aspx?clipid=272
BNN reaches Canada's most targeted audience of 1.7 million weekly and 6.3 million total retail and financial investors. With its focus on the financial industry, the broadcasts attract predominantly investors in stocks, bonds, and luxury goods over the age of 35 with average incomes of over $100,000 per year.
"BNN is Canada's premier business and financial news station reaching millions of households each week," said Abattis Bioceuticals Corp. CEO Mike Withrow. "We are excited to raise our profile among the Canadian investment community as we continue to execute on our business plan and build long-term value."
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.
ON BEHALF OF THE BOARD
"Mike Withrow"
Michael Withrow, President & CEO
For further information, contact the Company's CEO, Michael Withrow at (778) 896-6536 or at [email protected].
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY ORACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.
SOURCE: Abattis Bioceuticals Corp.